Beam, Inc. (BEAM) Tops Q3 EPS by 1c
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 10/6/2026
Go back to Beam, Inc. (BEAM) Tops Q3 EPS by 1c
November 5, 2024 2:56 PM EST
JPMorgan analyst Eric Joseph reiterated an Overweight rating and $48.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "Key updates alongside 3Q results (loss per share of $1.17) centered on the companys SCD/B-thal cell therapy franchise ahead of multiple presentations at... More
November 5, 2024 11:47 AM EST
Stifel analyst Benjamin Burnett reiterated a Buy rating and $69.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM)
The analyst comments "As expected from an initial update from a lead program, early BEAM-101 (sickle cell disease [SCD]) disclosure offers important takeaways that, understandably, trigger investor... More
November 5, 2024 8:58 AM EST
BMO Capital analyst Kostas Biliouris reiterated an Outperform rating and $57.00 price target on Beam Therapeutics Inc (NASDAQ: BEAM).
The analyst comments "The first-ever clinical data from BEAM's base editing platform in SCD demonstrate a robust BEAM-101 efficacy/safety profile with differentiating characteristics compared... More
